UCR School of Medicine to serve as lead site for clinical trial on stuttering.
The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.
Find the full article here: Emalex news release written by Evelyn M. O’Connor.